Journals / Turkish Journal of Hematology / 2013 / Cilt: 30 - Sayı: 1

Akut lenfoblastik lösemili bir çocukta EBV ilişkili lenfoproliferatif hastalığın santral sinir sistemi tutulumu: Rituximab ve interferon alfa ile başarılı tedavi

Central nervous system involvement of epstein barr virus associated lymphoproliferative disorder in a child with acute lymphoblastic leukemia: Successful treatment with rituximab and interferon-alpha

Pages
58–62
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Given the rarity of the complication in children receiving these agents, our experience with such a case may be helpful to others.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Central nervous system (CNS) involvement of Epstein-Barr virus (EBV)-associated lymphoproliferative disease is a rare and serious complication in children with leukemia.
📊
Key Findings & Data:Here we report isolated CNS involvement of EBV-associated lymphoproliferative disorder in a 4- year-old boy with acute leukemia.
💡
Conclusion & Impact:Given the rarity of the complication in children receiving these agents, our experience with such a case may be helpful to others.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Central nervous system (CNS) involvement of Epstein-Barr virus (EBV)-associated lymphoproliferative disease is a rare and serious complication in children with leukemia. Although rituximab therapy seems to be promising in these cases, persistent hypogammaglobulinemia may appear after treatment due to complete depletion of normal B lymphocytes in the peripheral blood. Here we report isolated CNS involvement of EBV-associated lymphoproliferative disorder in a 4- year-old boy with acute leukemia. The patient was treated with rituximab and interferon alpha; however, persistent hypogammaglobulinemia developed as a complication. Given the rarity of the complication in children receiving these agents, our experience with such a case may be helpful to others.

Özet

Santral sinir sisteminin EBV ilişkili lenfoproliferatif hastalığı nadir bir durum olup, çocukluk çağı lösemilerinin ciddi bir komplikasyonudur. Bu olgularda rituximab tedavisi faydalı olmakla birlikte, periferik kanda normal B lenfositlerinin tam kaybı sonucunda persistan hipogamaglobulinemi ortaya çıkabilmektedir. Burada akut lösemili 4 yaşında bir erkek çocukta, EBV ilişkili lenfoproliferatif hastalığın izole santral sinir sistemi tutulumu sunulmaktadır. Hasta rituximab ve alfa interferon ile tedavi edilmiş, ancak komplikasyon olarak persistan hipogamaglobulinemi gelişmiştir. Bu ilaçları kullanan çocuklarda nadir görülen bir komplikasyon olması nedeniyle, bu olgu ile elde ettiğimiz deneyimin diğerlerine yardımcı olacağını düşünmekteyiz.

🔖

Cite This Article

ATABAY, B., TÜRKER, M., ÖZTÜRK, C., SÜTÇÜOĞLU, S., ÖNİZ, H., ARUN, E. Ö. (2013). Akut lenfoblastik lösemili bir çocukta EBV ilişkili lenfoproliferatif hastalığın santral sinir sistemi tutulumu: Rituximab ve interferon alfa ile başarılı tedavi. Turkish Journal of Hematology, Cilt: 30 - Sayı: 1, 58–62. https://ajindex.com/articles/412588

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Hardy C, Feusner J, Harada S, Sanger W, Von Schmidt B, Yetz J, Saemundsen A, Lennette E, Linder J, Seeley JK, et al. Fatal Epstein-Barr virus-induced lymphoproliferation complicating acute lymphoblastic leukemia. J Pediatr 1984;105:64-67
  2. Taj MM, Hadzic N, Height SE, Wotherspoon A, Burke M, Hobson R, Viskaduraki M, Pinkerton CR. Long term outcome for immune suppression and immune related lymphoproliferative disorder: Prospective data from the UK CCLG Registry 1994-2004. Leuk Lymphoma 2012;53:842-848
  3. Yuksel-Soycan L, Aydogan G, Tanyeli A, Timur C, Erbay A, Oniz H, Patiroglu T, Yesilipek A, Soker M, Vural S, Pekun F Bor O, Sarper N, Cetingul N, Guler E, Polat A, Biner B, Caglar K, Goksan B, Gedikoglu G. BFM-TR ALL 2000: First Turkish multicentric study in the treatment of pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer 2006;47:426-427
  4. Rezk SA, Weiss LM. Epstein-Barr virus-associated lymphoproliferative disorders. Hum Pathol 2007;38:1293- 1304
  5. Bernard F Sarran N, Margueritte G, Barneon G, Astruc J. Successful treatment of an Epstein-Barr virus-associated B-cell lymphoproliferative disease in a child with acute lymphoblastic leukemia using an anti-CD20 monoclonal antibody. Med Pediatr Oncol 2001;36:329-331
  6. Look AT, Naegele RF Callihan T, Herrod HG, Henle W. Fatal Epstein-Barr virus infection in a child with acute lymphoblastic leukemia in remission. Cancer Res 1981;41:4280-4283
  7. Joncas JH, Russo P, Brochu P, Simard P, Brisebois J, Dube J, Marton D, Leclerc JM, Hume H, Rivard GE. Epstein-Barr virus polymorphic B-cell lymphoma associated with leukemia and with congenital immunodeficiencies. J Clin Oncol 1990;8:378-384
  8. Rohrlich P Lescoeur B, Rahimy C, Vilmer E, Brousse N, Foulon E. Epstein-Barr virus associated B-cell lymphoproliferation in an infant treated for acute lymphoblastic leukemia. Blood 1993;81:264
  9. Perkkiö M, Riikonen P, Seuri R, Vornanen M. Successful treatment of monoclonal, aggressive Epstein-Barr virus- associated B-cell lymphoproliferative disorder in a child with acute lymphoblastic leukemia. Med Pediatr Oncol 1999;32:447-449
  10. Mustafa MM, Winick NJ, Margraf LR. Epstein-Barr virus lymphoproliferative disorder in children with leukemia: case report and review of the literature. J Pediatr Hematol Oncol 1997;19:77-81
  11. Pondarre C, Kebaili K, Dijoud F Basset T, Philippe N, Bertrand Y. Epstein-Barr virus-related lymphoproliferative disease complicating childhood acute lymphoblastic leukemia: no recur